

Edgar Filing: TRANSGENOMIC INC - Form 8-K

TRANSGENOMIC INC
Form 8-K
January 16, 2004

=====

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
January 15, 2004

TRANSGENOMIC, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State of Formation)

000-30975
(Commission File Number)

911789357
(IRS Employer Identification Number)

12325 Emmet Street
Omaha, NE
(Address of principal executive offices)

68164
(Zip Code)

(402) 452-5400
(Registrants' telephone number, including area code)

Not applicable
(Former name or former address, if changed since last report)

=====

Item 5. Other Events and Regulation FD Disclosure.

On January 15, 2004, the Company issued a press release announcing that Nanogen Inc. and Transgenomic have entered into an agreement allowing Transgenomic to distribute Nanogen's NanoChip(R) Molecular Biology Workstation in selected Western European countries. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

Item 7. Financial Statements and Exhibits.

(c) Exhibits

99.1 Press Release, dated January 15, 2004, announcing that Nanogen Inc. and Transgenomic have entered into an agreement allowing Transgenomic to distribute Nanogen's NanoChip(R) Molecular Biology Workstation in selected Western European countries.

Edgar Filing: TRANSGENOMIC INC - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TRANSGENOMIC, INC.

By /s/ Michael J. Draper

Michael J. Draper, Chief Financial Officer

January 15, 2004